Prof. Dr. Ali Salanti is a professor at the Centre for Translational Medicine and Parasitology at the Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen in Copenhagen, Denmark. His core expertise is within translational research of recombinant biopharmaceuticals. He has been leading malaria vaccine projects from discovery to preclinical to production to clinical testing, as well as COVID-19 and HER2 vaccine developments. Besides immunological vaccine projects, his expertise is centered around protein: receptor interactions involving glycosaminoglycans. He was the first to define the antigen (VAR2CSA) responsible for malaria in pregnant women. Early in his career, he decided to devote his research to preparing VAR2CSA for human clinical trials. Recently, they finalized the clinical Phase Ia trial in Germany and Ib trial in Benin. A few years ago, they discovered the seminal finding that the molecule the malaria parasites bind to in the placenta is also present on all tested tumors and absent from normal tissue and is now dedicated to take this discovery to the clinic as a targeted pan-cancer therapy.
Prof. Dr. Ali Salanti is a professor at the Centre for Translational Medicine and Parasitology at the Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen in Copenhagen, Denmark. His core expertise is within translational research of recombinant biopharmaceuticals. He has been leading malaria vaccine projects from discovery to preclinical to production to clinical testing, as well as COVID-19 and HER2 vaccine developments. Besides immunological vaccine projects, his expertise is centered around protein: receptor interactions involving glycosaminoglycans. He was the first to define the antigen (VAR2CSA) responsible for malaria in pregnant women. Early in his career, he decided to devote his research to preparing VAR2CSA for human clinical trials. Recently, they finalized the clinical Phase Ia trial in Germany and Ib trial in Benin. A few years ago, they discovered the seminal finding that the molecule the malaria parasites bind to in the placenta is also present on all tested tumors and absent from normal tissue and is now dedicated to take this discovery to the clinic as a targeted pan-cancer therapy.